Aeglea begins dosing in Phase I/II trial of AEB1102 for arginase 1 deficiency

Aeglea BioTherapeutics has begun dosing patients in the repeat dose part of its Phase I/II clinical trial of AEB1102 (pegzilarginase) to treat arginase 1 deficiency.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news